[et_pb_section fb_built=”1″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]
Pages
- About Us
- Board of Directors
- Bora Prescription Drugs
- Bora Way
- Careers
- Consumer Healthcare
- Contact Us
- Functional Committee
- Home
- Internal Audit Operation
- IR Desk
- Leadership
- Media Kit
- Overview
- Sitemap
- Sustainability
- Sustainable Drug Supply
- Sustainable Environment
- Talent Development and Happy Workplace
- Young Talent Program
Posts by category
- Category: News Center
- Category: Business
- Bora Pharmaceuticals Wins World Finance Sustainability Award 2025
- Bora Adds Automated Fill/Finish Line in Baltimore
- Tanvex BioPharma Completes Acquisition of Bora Biologics, Launching New Era in Biologics Development
- 泰福生技完成合併保瑞生技 台灣最大國際級CDMO戰隊正式成軍 攜手強攻全球生物製劑代工市場 開啟成長新篇章
- Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio’s Tri-Specific Antibody to Treat Cancer
- Bora Pharmaceuticals Announces Unveiling of New Multi-Purpose Small Molecule Site in Zhongli, Taiwan
- Bora Pharmaceuticals Wins Dual Honors at the Taiwan MAPECT M&A Ceremony: “Deal of the Year” Award and “Best Cross-Border M&A” Award
- Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals
- Bora Pharmaceuticals Makes a Strategic Investment into Tanvex to Provide Global BioManufacturing Services.
- Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent
- Bora Recognized with Dual Accolades at Asia Best Companies to Work for Awards 2024
- Bora Pharmaceuticals Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility
- Bora Wins Presidential Innovation Award, Award Prize Donation to Benefit Those Impacted by Earthquake
- Bora Pharmaceuticals Completes the Acquisition of Upsher-Smith
- SunWay Biotech and Gnosis by Lesaffre Form Alliance to Launch MenaQ7® Metabolic, featuring the ANKASCIN® 568-R ingredient
- Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion
- Bora Pharmaceuticals Celebrates Integration with SunWay Biotech, Embarking on a Global Journey
- Bora Recognized at “2023 Most Outstanding Company of the Year Awards.” Ceremony Attended by President Tsai Ing-wen
- Bora Pharmaceuticals unveils eye-opening new facility for Ophthalmic manufacturing
- Bora Pharmaceuticals is Awarded Outstanding Company of the Year at Bio-Asia Taiwan 2023
- 保瑞藥業獲頒2023年傑出生技產業金質獎
- Bora Pharmaceuticals and Celltrion Partners to Expand OSD capabilities in APAC market
- Bora expands its CDMO capabilities as it makes landmark acquisition of TWi Pharmaceuticals
- Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan’s CDMO sector as it continues to expand into the global CDMO market
- Bora Pharmaceuticals to expand operations with $10m investment
- Bora Pharmaceuticals collaborates with Taishin Holdings to launch CDMO investment and M&A plan
- KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to manufacture generic product for filing in Japan
- CEO Bobby Sheng wins CEO of the Year at CPhI Awards 2020
- 製藥品質受肯定 保瑞獲國際大獎
- Best Companies to Work for in Taiwan 2019 Awards
- 2019 台灣最佳企業雇主獎
- 2018台灣併購金鑫獎頒獎典禮
- 2018 Taiwan MAPECT Taiwan M&A Awards
- 12th Annual Top 10 Potential Business Gold Torch Award
- 12th Annual Top 10 Potential Business Gold Torch Award
- Category: Community
- Category: Events
- Category: Investors
- Category: People
- Category: Business
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]